Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
18 February, 2019 01:41 IST
Strides Shasun receives USFDA nod for Cyproheptadine HCl tablets
Source: IRIS | 12 Apr, 2018, 12.00PM
Comments  |  Post Comment

Strides Shasun today announced that its wholly owned subsidiary Strides Pharma Global has received approval for Cyproheptadine Hydrochloride Tablets USP, 4 mg from the United States Food & Drug Administration (US FDA). Cyproheptadine Hydrochloride Tablets is a generic version of Periactin Tablets of Merck & Co. Inc.

According to IQVIA data, the US market for Cyproheptadine Hydrochloride Tablets USP, 4 mg is approximately USD 20 Million. The product will be manufactured at the company's Oral dosage facility at Bangalore and will be marketed by Strides Pharma Inc. in the US Market.

The company has 74 cumulative ANDA filings with USFDA of which 46 ANDAs have been approved as of date and 28 are pending approval.

Shares of the company declined Rs 8.1, or 1.26%, to trade at Rs 633.75. The total volume of shares traded was 15,613 at the BSE (11.47 a.m., Thursday).



Strides Pharma Science Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Lupin launches Clobazam oral suspension - 15-Feb-2019 16:37
Muthoot Finance to raise upto Rs 7.50 bn through NCDs - 14-Feb-2019 11:01
Zydus gets USFDA nod for Triamterene & Hydrochlorothiazide capsules - 13-Feb-2019 13:10
L&T Construction bags contract for construction of hospitals - 13-Feb-2019 11:56
Strides receives USFDA approval for Triamcinolone Acetonide cream - 13-Feb-2019 11:52
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer